4 results
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
The purpose of this study is to compare the effect of AT1001 (migalastat hydrochloride) versus placebo on GL-3 in the kidney.
Primary Objective: to explore whether UVB exposure leads to detectable changes of the biomarkers of the skin barrier, immune response and DNA-damage in urine and stratum corneum Secondary Objective(s): to explore the profile of biomarkers in…
The objective of this study is to validate the tHb determined by sOCT by comparing it to the tHb from invasive blood sampling. From this comparison, we aim to optimize our data analysis procedure for in vivo sOCT measurements. We also aim to…